NCT00310232 2024-04-02
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Ontario Clinical Oncology Group (OCOG)
Phase 3 Terminated
Clinical Trials
12 trialsNCT00254436 2018-10-25
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00495378 2016-12-20
RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia
Ortho Biotech Products, L.P.
Phase 4 Terminated
NCT00267007 2014-06-04
A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00386152 2013-07-19
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00017277 2012-09-24
Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00005787 2012-06-01
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
Northwestern University
Phase 1 Terminated
NCT00210730 2011-06-10
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00246597 2011-05-19
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00350090 2011-05-19
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00083434 2011-04-27
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00083486 2011-04-27
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated